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Background: Oxidative stress (OS) is said to increase in hemodialysis therapy, so that the electrolyzed water-hemodialysis
(EW-HD) dissolving hydrogen in hemodialysis fluid has been tried for the reduction of OS. It is reported that the risk of
cardiovascular disease events increased if the fraction of reduced albumin (human mercaptalbumin (f(HMA))) was low
and that the f(HMA) rose at the dialyzer outlet on EW-HD. Therefore, we studied whether the f(HMA) of hemodialysis
patients was improved when they received long-term EW-HD treatment.
Methods: We produced hydrogen-dissolved hemodialysis fluid with EW-C81-HD and carried out EW-HD
treatment for 12 patients. The serum albumin redox states of pre- and post-HD were measured in the summer
of 2014 (EWHD2014) and in the winter of 2015 (EWHD2015) after 6 months by high-performance liquid
chromatography using Shodex-Asahipak ES-502N 7C column. For comparison, 38 conventional hemodialysis
(C-HD) patients and 24 healthy subjects were selected.
Results: The f(HMA) of EWHD2015 significantly increased from EWHD2014 on both pre- and post-HD (pre, 51.
32 ± 5.63 %→ 58.03 ± 7.43 %; post, 72.04 ± 5.73 %→ 76.42 ± 4.67 %). The f(HMA) of C-HD at pre- and post-HD
were 51.07 ± 9.07 and 70.53 ± 8.05 %, respectively. The f(HMA) of healthy subjects was 79.11 ± 5.46 %. The
f(HMA) of EWHD2014 at pre-HD evidenced no significant difference with that of C-HD at pre-HD, but the f(HMA)
of EWHD2015 at pre-HD was significantly higher than that of C-HD at pre-HD. The f(HMA) of C-HD at post-HD
was significantly lower than that of both EWHD2015 at post-HD and healthy subjects, but the f(HMA) of
EWHD2015 at post-HD showed no significant difference with that of healthy subjects.
Conclusions: Our data suggest that the f(HMA) may be raised with long-term hemodialysis treatment using
hydrogen-dissolved hemodialysis fluid.
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The dialysis patient population in Japan was 310,007
at the end of 2012. The characteristics of the dialysis
patients include the long dialysis vintage, aging, and
increased rate of diabetic nephropathy on primary
disease. The patient population surviving over 25 years
of dialysis was 12,307 (4.1 %). Their mean age was
66.9 years, and the percentage over 75 years of age
was 29.6 %. On the primary disease, the percentage
of diabetic nephropathy was 37.1 % and that of
chronic glomerulonephritis was 33.6 % [1]. The life
convalescence of a dialysis patient is far worse than
that of the general population [2], and one of the
main causes is considered to be oxidative stress (OS)
related with hemodialysis therapy [3, 4]. One of the
OS markers was the albumin oxidation-reduction ra-
tio [5]. The reduced form of albumin decreases from
a point of chronic kidney disease before the dialysis
therapy [6], and that is lower in hemodialysis and
peritoneal dialysis patients. The cardiovascular event
and death risk are as high as the reduced form of al-
bumin is low [7, 8].
In present dialysis therapy, various kinds of treatments
are carried out to reduce the risk of mortality and the
frequency of complications. The hydrogen molecules re-
move a hydroxyl radical and reduce the OS [9], so its
effects are expected on the hemodialysis therapy.
The electrolyzed water-hemodialysis (EW-HD) dissolv-
ing hydrogen in hemodialysis fluid is one of the various
kinds of treatments to reduce OS. The EW-HD treat-
ment was first reported by Huang et al. [10]. In Japan,
the clinical application of EW-HD was carried out by
Nakayama et al. [11]. Its effects such as anemia improve-
ment, blood pressure control, and the reduction of the
OS were then reported [12, 13].
We began the EW-HD treatment from January 2014
in Daiko Sunadabashi Branch Clinic, too, and began
examining clinical effects of EW-HD from July. One pre-




Age (years old) 70 (57–83)
Primary disease (DM/non-DM) 6/6
Body weight at post-HD (kg) 48.7(43.7–64.7)
HD treatment time (hours) 4.0 (3.5–4.0)
HD vintage (months) 8 (1–150)
EW-HD vintage (days) 75 (19–210)
There was no significant difference between EW-HD and C-HD
aAt 2014more effectively than conventional HD (C-HD) session.
In this report, the authors adapted the redox state of hu-
man serum albumin (HSA-redox) as a marker of OS:
they found that a fraction of reduced albumin (human
mercaptalbumin (f(HMA))) rose at the dialyzer outlet
only on EW-HD treatment [14]. However, there is still
no long-term study regarding the long-term effect of
EW-HD on HSA-redox profile. Therefore, we studied
whether the f(HMA) of HD patients increased when
they received long-term EW-HD treatment. This is why
we report here this interesting f(HMA) increase with
long-term EW-HD treatment.Methods
Subject
Twelve patients (male/female; 6/6) received EW-HD, 38
(male/female; 24/14) received C-HD, and 24 people were
healthy subjects (male/female; 11/13). The age and/or
other parameters are shown in Table 1. No patient who
took a drug had a reduction action.
Primary disease, age, and sex were not required for the
condition of the subjects, but the patients having cirrho-
sis or a malignant tumor were excluded.Production of the hydrogen-dissolved hemodialysis fluid
The reverse osmosis water dissolving hydrogen (H2-RO
water) that was produced by the Reverse Osmosis
Purified Water Production System for EW-HD; EW-
C81-HD (Trim Medical Institute Co., Ltd. Sendai, Japan)
was used for the product water. The hydrogen-dissolved
hemodialysis fluid was produced by the Multiple Patient
Dialysis Fluid Supply System; DAB-20NX (NIKKISO
Co., Ltd. Tokyo, Japan). The concentrated liquid for
hemodialysis fluid was produced by Dialysis Powder
Mixing Device; DAD-50 (NIKKISO Co., Ltd. Tokyo,
Japan) using H2-RO water and Dialysis Powder; D
DRY®-2.5S/3.0S (NIKKISO Co., Ltd. Tokyo, Japan).
(Fig. 1).C-HD Healthy subjects
24/14 11/13
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Fig. 1 Schema of production process of hydrogen-dissolved hemodialysis fluid
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The dialysis conditions for the hemodialysis patients are
shown in Table 2. All patients did not receive hemodia-
filtration treatment. There were no differences in treat-
ment time, hemodialysis frequency, dialyzer type and
membrane material, membrane area, quantity of bloodTable 2 Dialysis condition
EW-HD (n = 12) EWHD2014→ EWHD01
Treatment mode Hemodialysis
Treatment time (hour/session) 3.92 ± 0.19→ 3.96 ± 0.14
Hemodialysis frequency 3 times/week
Dialyzer type/membrane material V/PS: 6; IV/CTA: 6→ V/PS: 7; IV/CTA: 5
Dialyzer membrane area (m2) 1.5 (1.3–2.1)→ 1.7 (1.5–2.1)
QB (mL/min) 200 (180–230)→ 200 (200–230)
QD (mL/min) 500
Dialysis dose: KT/V for urea 1.45 ± 0.15→ 1.55 ± 0.19
Body weight pre-HD (kg) 52.9 ± 6.4→ 54.3 ± 6.3
post-HD (kg) 50.7 ± 6.4→ 51.9 ± 6.5
Dialysis powder D DRY®-2.5S/3.0S











ns no significant difference between EW-HD and C-HDflow (QB), or dialysis dose between EW-HD and C-HD.
The quantity of hemodialysis fluid flow (QD) was
500 mL/min in all patients. The dialysis powder of C-
HD was Kindaly 4E (Fuso Pharmaceutical Industries,
Ltd., Osaka, Japan). The compositions of hemodialysis
fluid in C-HD are almost the same as those in EW-HD.5 C-HD (n = 38) Notes
Hemodialysis
3.95 ± 0.48 Mean ± SD ns
3 times/week
V/PS: 14; IV/PS: 8, CTA: 16 Polysulfone (PS), cellulose triacetate (CTA)
1.8 (1.3–2.5) Median (min−max) ns
200 (150–250) Median (min−max) ns
500
1.45 ± 0.24 Mean ± SD ns
56.6 ± 11.5 Mean ± SD ns










Maeda et al. Renal Replacement Therapy  (2016) 2:42 Page 4 of 8Measurements
HMA and HNA (human nonmercaptalbumin) were mea-
sured by high-performance liquid chromatography (HPLC)
as reported in the previous paper [14]. Briefly, the HPLC
system consisted of an AS-8010 auto-sampler (Tosoh,
Tokyo, Japan; 2 μL injection volume) and a CCPM double-
plunger pump (Tosoh) in conjunction with a CO-8011 sys-
tem controller (Tosoh). Chromatographs were obtained
using a UV6000LP photodiode alley detector (detection
area, 200–600 nm with 1 nm step; Thermo Electron,
Waltham, MA, USA). A Shodex-Asahipak ES-502 N 7C
column (10 × 0.76 cm I.D., DEAE form for ion-exchange
HPLC; Showa Denko, Tokyo, Japan; column temperature,
35 ± 0.5 °C) was used in this study.
The f(HMA) was calculated with the following equation,
f(HMA) = [HMA/(HMA+HNA)] × 100 (%).
The serum samples were collected from EW-HD
patients in August/September 2014 (EWHD2014) and
February/March 2015 (EWHD2015), from C-HD pa-
tients in August 2014 ~ February 2015, from healthy
subjects in September/October 2014. The samples were
frozen at −80 °C until measurement. The sampling from
the patients was carried out at the pre- and post-HD at
the beginning of the week.
The hydrogen concentration in hemodialysis fluid was
measured by Portable Dissolved Hydrogen Meter; DH-
35A (DKK-TOA CO., LTD. Tokyo, Japan).
Data analysis
The data were shown in mean ± standard deviation. The
Stat View 5.0 (Hulinks Inc., Tokyo, Japan) software was
used for statistical tests. The differences of EWHD2014
and EWHD2015 were compared by paired t test. The
multiple comparison procedure was carried out for stat-
istical analysis among EW-HD, C-HD, and healthy sub-
jects. We assumed less than 5 % of levels of significance
as a statistical significance standard.
Results
The f(HMA) of pre- and post-HD were 51.32 ± 5.63 and
72.04 ± 5.73 % at EWHD2014, respectively. The f(HMA)
of pre- and post-HD were 58.03 ± 7.43 and 76.42 ±
4.67 % at EWHD2015, respectively. The f(HMA) of pre-
and post-HD on C-HD were 51.07 ± 9.07 and 70.53 ±Table 3 Albumin redox of patients and healthy subjects
EWHD2014 (n = 12) EWHD2015 (n = 12)
Pre-HD Post-HD Pre-HD P
f(HMA) 51.32 ± 5.63 72.04 ± 5.73 58.03 ± 7.43 7
f(HNA) 48.68 ± 5.63 27.96 ± 5.73 41.97 ± 7.43 2
f(HMA) fraction of human mercaptalbumin, f(HNA) fraction of human nonmercaptal
f(HNA) = 100 − f(HMA)8.05 %, respectively. The f(HMA) of healthy subjects was
79.11 ± 5.46 % (Table 3).
Table 4 shows the blood data of the patients at the
time of sampling.
On the EW-HD, the f(HMA) at 2015 significantly in-
creased from 2014 on both pre- and post-HD (Fig. 2).
On comparison with C-HD at pre-HD, the f(HMA) of
EWHD2014 showed no significant difference with that
of C-HD, but the f(HMA) of EWHD2015 was signifi-
cantly higher than that of C-HD (Fig. 3).
In the relationship between the HD vintage and
f(HMA) at pre-HD, there were no correlation both in C-
HD and EWHD2014(Fig. 4).
On comparison among EWHD2015, C-HD and
healthy subjects, the f(HMA) of C-HD at post-HD were
significantly lower than those of EWHD2015 at post-HD
and healthy subjects, but the f(HMA) of EWHD2015 at
post-HD showed no significant difference with that of
healthy subjects (Fig. 5).
The concentration of hydrogen in hemodialysis fluid
was measured several times after the beginning of EW-
HD, and ranged 47~196 ppb (Table 5).
Discussion
Albumin is the main antioxidant in plasma [5], and we
paid attention to HSA-redox and examined it. As for the
human albumin, the free thiol of 34-cysteine is reduced
albumin (HMA), and the disulfide bond of 34-cysteine is
oxidative albumin (HNA). HMA plays an important role
in the antioxidant mechanism in extracellular fluid [5].
The f(HMA) in serum decreases with aging, but that in
cerebrospinal fluid does not change [15]. The control
mechanism of albumin redox has not fully been exam-
ined, but Matsuyama et al. reported that human astro-
cytes and aortic endothelial cells are actively converted
to HMA from HNA [15]. The f(HMA) decreases with a
renal dysfunction [6], so the kidney may do some kind
of participation in albumin redox. In the hemodialysis
patients who have almost no renal function, it is thought
that the albumin redox adjustment function is lowered
during non-hemodialysis treatment. In the albumin
redox of hemodialysis patients, the f(HMA) increased to
nearly normal levels post-HD when hemodialysis treat-
ment was performed, but decreased afterward , and was(%) mean ± SD




6.42 ± 4.67 51.07 ± 9.07 70.53 ± 8.05 79.11 ± 5.46
3.58 ± 4.67 48.93 ± 9.07 29.47 ± 8.05 20.89 ± 5.46
bumin
Table 4 Data of blood and physical situation in patients
Mean ± SD
EWHD2014 (n = 12) EWHD2015 (n = 12) C-HD (n = 38)
BUN (mg/dL) 56.05 ± 11.25 56.53 ± 13.39 62.27 ± 12.73
Cr (mg/dL) 8.98 ± 2.32 9.20 ± 1.78 10.05 ± 2.4
UA (mg/dL) 6.99 ± 1.21 6.98 ± 1.12 6.84 ± 1.29
Hb (g/dL) 10.91 ± 1.033 10.98 ± 0.73 11.26 ± 1.20
WBC (/μL) 6121 ± 2493 6605 ± 2039 5827 ± 2046
CRP (mg/dL) 0.552 ± 1.015a 0.542 ± 0.747 0.234 ± 0.492b
Alb (g/dL) 3.49 ± 0.20 3.65 ± 0.24* 3.53 ± 0.23
GOT (U/L) 13.3 ± 2.4 14.1 ± 2.3 31.4 ± 105.0
GPT (U/L) 9.2 ± 2.8 10.3 ± 5.0 25.5 ± 88.1
T-Cho (mg/dL) 154 ± 39 165 ± 47 146 ± 24
nPCR (g/kg/day) 0.81 ± 0.13 0.83 ± 0.16 0.87 ± 0.15
%CGR (%) 93.2 ± 32 98.2 ± 27 99.0 ± 25.4
BMI (kg/m2) 20.1 ± 2.9 20.6 ± 3.2* 21.5 ± 3.3
GNRI (−) 89.2 ± 5.0 92.1 ± 6.3** 91.3 ± 5.1
*p < 0.05 (paired t-test vs EWHD2014); **p < 0.01 (paired t-test vs EWHD2014)
Other data were no significant difference
an = 10
bn = 13
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ment [16]. The data of our study indicated similar re-
sults but the significant difference with healthy subjects
was not only the f(HMA) of post-HD in EWHD2015,
but the low numerical value.
As to previous study regarding the relationship be-
tween HSA-redox and EW-HD, Terawaki et al. [14] re-












Fig. 2 Comparison of the f(HMA) on EWHD2014 vs EWHD2015. n = 12: botHSA-redox [14]. Our present study, however, deals with
the long-term (201~392 days) effect of EW-HD treat-
ment on HSA-redox profile. In our study, data were col-
lected at only one point in C-HD; however, it was
thought that there was little possibility of the change by
HD vintage (Fig. 4). It is suggested that the f(HMA) of
hemodialysis patients improves with long-term EW-HD
treatment.p=0.0404













(n=38)                                      (n=12) (n=12)
p=0.0452
p=0.9957
Fig. 3 Comparison of the f(HMA) in pre-HD
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disease (CVD) events and mortality were very high at
pre-HD f(HMA) <40 % or post-HD f(HMA) <60 %; in
particular, the odds ratios of CVD incidence and mortal-
ity in the post-HD f(HMA) < 60 % were 20.6 and 25.6
times by those in the post-HD f(HMA) ≥60 %, respect-
ively [7]. In our study, the C-HD treatment patients who
were f(HMA) <40 % at pre-HD were 4 (10.5 %) and,
those of the f(HMA) < 60 % at post-HD were 3 (7.9 %),
but no EW-HD treatment patient corresponded to those
conditions.y = -0.0008x + 51.878
R² = 0.0077



















C-HD preHD C-HD postHD
Fig. 4 Relationship of the HD vintage and f(HMA)The pre-HD albumin levels at EWHD2015 were sig-
nificantly increased compared with those at EWHD2014,
to 3.65 from 3.49 g/dL, likewise BMI and GNRI were
significantly increased (Table 4). If all the rising values
were HMA, the f(HMA) increased only to 53.45 from
51.32 %. And, the dialyzer and/or the reduction of body
weight that influence on albumin leakage during
hemodialysis were no different between EWHD2014 and
EWHD2015 (Table 2). Therefore, EW-HD is more likely to
contribute to the rise of HMA. Long-term EW-HD treat-
ment presumably resulted in the rise of HMA by they = -0.0013x + 52.561
R² = 0.088
y = 0.0002x + 71.838
R² = 0.0023
2555 2920 3285 3650 4015 4380 4745
e (day)






















Fig. 5 Comparison of the f(HMA) in post-HD and healthy subjects
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[14] and/or the improvement of blood vessel wall function
[15]. In a comparison of EWHD2014 and EW2015, the pre-
HD f(HMA) values increased and the difference in the
f(HMA) value between pre- and post-HD decreased. It is
thought that the latter contribution is greater, and the
possible effectiveness of the prevention of CVD events by
long-term EW-HD treatment was suggested.
Nakayama et al. reported that EW-HD ameliorated in-
flammatory reactions and offered a novel therapeutic op-
tion for control of uremia [17]. Huang et al. reported
that 1-year treatment improved T cell damage [18]. MIA
syndrome has been proposed as one of the disease states
influencing the vital prognosis of hemodialysis patients.
MIA syndrome is a syndrome that occurs in relation to
malnutrition, inflammation and atherosclerosis, of which
inflammation is considered to take a central role [19].
The inflammatory reaction and the oxidation LDL gen-
eration may be decrease directly or indirectly by the
reduction action of hydrogen, so we expect that longer-Table 5 Hydrogen concentration of the EW-HD fluid






Concentration unit is ppbterm EW-HD treatment will show clinical usefulness
such as a lower frequency of complications and/or
improvement of vital prognosis.
Study limitations
There are several limitations in this study. The number
of EW-HD subjects is small, and the observation period
in EW-HD treatment is not sufficient to detect any clin-
ical outcome. It will therefore be necessary to evaluate
albumin redox in more patients with longer-term EW-
HD treatment.
Conclusions
Our data suggest that the f(HMA) may be raised with
long-term hemodialysis treatment using hydrogen-
dissolved hemodialysis fluid.
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